In this study, we found that the expression of BCL2A1 in glioma was significantly higher than that in NBTs at both the mRNA and protein levels according to a comprehensive analysis of public databases and an in-house cohort that included 10 NBTs and 174 glioma samples. The gene discussed is BCL2A1; the disease is central nervous system cancer.